Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 108,309 | 100,496 | 103,348 | 90,703 | 89,343 |
| Cost of Goods | 9,914 | 12,257 | 5,319 | 8,631 | 8,270 |
| Gross Profit | 98,395 | 88,239 | 98,029 | 82,072 | 81,073 |
| Operating Expenses | 247,266 | 242,601 | 243,976 | 307,769 | 222,936 |
| Operating Income | -147,957 | -154,105 | -145,628 | -225,066 | -141,593 |
| Interest Expense | 15,375 | 15,636 | 15,874 | 14,505 | 6,052 |
| Other Income | 4,236 | 6,264 | 8,218 | 752 | -10,215 |
| Pre-tax Income | -159,096 | -163,477 | -153,284 | -238,819 | -157,860 |
| Income Tax | 732 | 495 | -1,451 | 6,287 | 302 |
| Net Income Continuous | -159,828 | -163,972 | -151,833 | -245,106 | -158,162 |
| Net Income | $-159,828 | $-163,972 | $-151,833 | $-245,106 | $-158,162 |
| EPS Basic Total Ops | -2.25 | -2.33 | -2.17 | -3.50 | -2.26 |
| EPS Basic Continuous Ops | -2.25 | -2.33 | -2.17 | -3.50 | -2.26 |
| EPS Diluted Total Ops | -2.25 | -2.33 | -2.17 | -3.50 | -2.26 |
| EPS Diluted Continuous Ops | -2.25 | -2.33 | -2.17 | -3.50 | -2.26 |
| EBITDA(a) | $-145,815 | $-151,863 | $-142,321 | $-219,403 | $-135,626 |